
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is advancing its clinical-stage pipeline of next-generation programmed T-cell therapies, with a heightened focus on achieving substantial improvements in manufacturing processes that could lead to gross margins of 60-70% over time. The strong efficacy and safety data from pivotal studies, particularly regarding Aucazyl's performance, suggest that the drug may significantly outperform existing treatments, potentially establishing itself as the preferred CAR-T therapy in specific market segments. Furthermore, observed lower exhaustion markers correlated with improved patient outcomes, reinforcing the potential of Autolus's therapeutic innovations in enhancing treatment effectiveness in oncology.
Bears say
Autolus Therapeutics faces a challenging outlook as projected sales for 3Q:25 are expected to remain flat quarter-over-quarter due to recent changes in CMS reimbursement policies, with a potential recovery not anticipated until 4Q:25. Additionally, production capabilities for CAR-T therapeutics may not meet expectations, indicating potential shortfalls in revenue generation. The presence of adverse events such as cytokine release syndrome and neurotoxicity raises concerns about the broader applicability and market acceptance of Autolus's therapies, further contributing to the negative financial sentiment surrounding the company's stock.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares